Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 5/20 | 0.81 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.81 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.81 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.81 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.81 |
| ▸ | RHOC | P08134 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | THRB | P10828 | 1/20 | 0.81 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.81 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.81 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.78 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.78 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.78 |
| ▸ | PDE6D | O43924 | 4/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL538508 | 1.00 | HMGCR (0.81) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL15475115 | 1.00 | HMGCR (0.81) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL12520033 | 1.00 | HMGCR (0.81) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL518254 | 0.95 | HMGCR (0.73) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL13450913 | 0.95 | HMGCR (0.72) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL21637553 | 0.94 | PDE6D (0.76) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL8931058 | 0.94 | HMGCR (0.86) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL469704 | 0.92 | HMGCR (0.68) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL9976581 | 0.92 | HMGCR (0.86) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL5240504 | 0.92 | HMGCR (0.86) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2413911-B1 | PROGRESSIVE EMULSION CRYSTALLIZATION | KRKA D D NOVO MESTO (SI) | 2014-02-19 | — | — | EP | claimed |
| EP-2413911-A1 | PROGRESSIVE EMULSION CRYSTALLIZATION | KRKA, D.D., Novo Mesto (SI) | 2012-02-08 | — | — | EP | claimed |
| US-20100260851-A1 | Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium | ACTAVIS GROUP PTC EHF (IS) | 2010-10-14 | — | — | US | claimed |
| WO-2010112222-A1 | PROGRESSIVE EMULSION CRYSTALLIZATION | KRKA, D.D., NOVO MESTO (SI) | 2010-10-07 | — | — | WO | claimed |
| US-20100197941-A1 | Process for the production of atorvastatin calcium in amorphous form | RANBAXY LABORATORIES LIMITED (IN) | 2010-08-05 | — | — | US | claimed |
| EP-2185527-A2 | NOVEL POLYMORPH OF ATORVASTATIN CALCIUM AND USE THEREOF FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM | Actavis Group PTC EHF (IS) | 2010-05-19 | — | — | EP | claimed |
| WO-2009007856-A2 | NOVEL POLYMORPH OF ATORVASTATIN CALCIUM AND USE THEREOF FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM | ACTAVIS GROUP PTC EHF (IS) | 2009-01-15 | — | — | WO | claimed |
| EP-1659110-A1 | Process for the production of atorvastatin calcium un amorphous form | Ranbaxy Laboratories Limited (IN) | 2006-05-24 | — | — | EP | claimed |
| WO-2020016903-A1 | AN IMPROVED AND COMMERCIALLY VIABLE PROCESS FOR PREPARATION OF PYRROLE DERIVATIVES WITH IMPROVED IMPURITY PROFILE & MINIMISATION OF UNIT OPERATIONS. | ARCH PHARMALABS LIMITED (IN) | 2020-01-23 | — | — | WO | disclosed |
| US-20140080984-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | ZANNA SCITECH CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| EP-2413911-B1 | PROGRESSIVE EMULSION CRYSTALLIZATION | KRKA D D NOVO MESTO (SI) | 2014-02-19 | — | — | EP | disclosed |
| EP-2413911-B1 | PROGRESSIVE EMULSION CRYSTALLIZATION | KRKA D D NOVO MESTO (SI) | 2014-02-19 | — | — | EP | disclosed |
| EP-2240442-B1 | PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN | MEDICHEM KOREA CO LTD (KR) | 2012-06-20 | — | — | EP | disclosed |
| US-8178697-B2 | Method for the preparation of atorvastatin and intermediates used therein | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2012-05-15 | — | — | US | disclosed |
| US-20090018182-A1 | Crystalline forms of atorvastatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-01-15 | — | — | US | disclosed |
| WO-2008117154-A2 | STABLE PHARMACEUTICAL COMPOSITIONS OF HMG-COA REDUCTASE INHIBITOR AND PROCESS FOR PREPARATION THEREOF | TORRENT PHARMACEUTICALS LIMITED (IN) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008053312-A2 | PROCESS FOR PREPARING AMORPHOUS ATORVASTATIN HEMI CALCIUM SALT AND ITS INTERMEDIATE | CADILA PHARMACEUTICALS LIMITED (IN) | 2008-05-08 | — | — | WO | disclosed |
| US-20060199855-A1 | Process for producing atorvastatin hemicalcium | APOTEX PHARMACHEM INC. | 2006-09-07 | — | — | US | disclosed |
| EP-1659110-A1 | Process for the production of atorvastatin calcium un amorphous form | Ranbaxy Laboratories Limited (IN) | 2006-05-24 | — | — | EP | disclosed |
| EP-1577297-A1 | Process for the production of atorvastatin calcium in amorphous form | RANBAXY LABORATORIES, LTD. (IN) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199855-A1 | Process for producing atorvastatin hemicalcium | DHCR7, ACSL3, NR1H3 | HMGCR 4/4885SLCO1B1 292/4885ABCB11 167/4885 |
| US-20090018182-A1 | Crystalline forms of atorvastatin | HMGCR, LIPA, ACAT2 | HMGCR 1/4885SLCO1B1 409/4885ABCB11 2387/4885 |
| US-20100260851-A1 | Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium | HMGCR, CYP4A11, CACNA1H | HMGCR 1/4885SLCO1B1 525/4885ABCB11 480/4885 |
| US-20100197941-A1 | Process for the production of atorvastatin calcium in amorphous form | HMGCR, CACYBP, SARAF | HMGCR 1/4885SLCO1B1 433/4885ABCB11 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.